In vitro analysis of virus particle subpopulations in candidate live-attenuated influenza vaccines distinguishes effective from ineffective vaccines.
Two effective (vac+) and two ineffective (vac-) candidate live-attenuated influenza vaccines (LAIVs) derived from naturally selected genetically stable variants of A/TK/OR/71-delNS1[1-124] (H7N3) that differed only in the length and kind of amino acid residues at the C terminus of the nonstructural NS1 protein were analyzed for their content of particle subpopulations. These subpopulations included total physical particles (measured as hemagglutinating particles [HAPs]) with their subsumed biologically active particles of infectious virus (plaque-forming particles [PFPs]) and different classes of noninfectious virus, namely, interferon-inducing particles (IFPs), noninfectious cell-killing particles (niCKPs), and defective interfering particles (DIPs). The vac+ variants were distinguished from the vac- variants on the basis of their content of viral subpopulations by (i) the capacity to induce higher quantum yields of interferon (IFN), (ii) the generation of an unusual type of IFN-induction dose-response curve, (iii) the presence of IFPs that induce IFN more efficiently, (iv) reduced sensitivity to IFN action, and (v) elevated rates of PFP replication that resulted in larger plaques and higher PFP and HAP titers. These in vitro analyses provide a benchmark for the screening of candidate LAIVs and their potential as effective vaccines. Vaccine design may be improved by enhancement of attributes that are dominant in the effective (vac+) vaccines.
Marcus
Philip I
PI
Department of Molecular and Cell Biology, Center of Excellence for Vaccine Research, University of Connecticut, U-3125, 91 North Eagleville Rd., Storrs, CT 06269, USA. philip.marcus@uconn.edu
Ngunjiri
John M
JM
Sekellick
Margaret J
MJ
Wang
Leyi
L
Lee
Chang-Won
CW
D003673:Defective Viruses; D014644:Genetic Variation; D007252:Influenza Vaccines / Q000145:classification / Q000592:standards*; D007372:Interferons / Q000096:biosynthesis; D008722:Methods; D014613:Vaccines, Attenuated / Q000145:classification / Q000592:standards*; D017361:Viral Nonstructural Proteins / Q000235:genetics / Q000627:therapeutic use; D010948:Viral Plaque Assay; D014771:Virion / Q000145:classification*; D014779:Virus Replication
C085820:INS1 protein, influenza virus; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D017361:Viral Nonstructural Proteins; D007372:Interferons